Gyroscope Therapeutics Revenue and Competitors

London, UK

Location

$269.5M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Gyroscope Therapeutics's estimated annual revenue is currently $4.7M per year.(i)
  • Gyroscope Therapeutics's estimated revenue per employee is $77,500
  • Gyroscope Therapeutics's total funding is $269.5M.

Employee Data

  • Gyroscope Therapeutics has 61 Employees.(i)
  • Gyroscope Therapeutics grew their employee count by -69% last year.

Gyroscope Therapeutics's People

NameTitleEmail/Phone
1
VP Quality AssuranceReveal Email/Phone
2
Head Research And DevelopmentReveal Email/Phone
3
VP & Head Corporate DevelopmentReveal Email/Phone
4
EVPReveal Email/Phone
5
VP, People and Organisational DevelopmentReveal Email/Phone
6
Associate Director Clinical OperationsReveal Email/Phone
7
Snr IT Director & Systems Integration Lead at Gyroscope Therapeutics, A Novartis CompanyReveal Email/Phone
8
Medical Affairs Director (USA Regional Lead)Reveal Email/Phone
9
Senior Director, Associate General CounselReveal Email/Phone
10
Associate Director CMC Analytical DevelopmentReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.5M29-12%N/AN/A
#2
$15.7M1015%N/AN/A
#3
$87.9M40525%$292MN/A
#4
$2.6M47016%$631.7MN/A
#5
$14.9M96-8%$81MN/A
#6
$44.8M2310%$132.9MN/A
#7
$7.6M49-37%N/AN/A
#8
$17.4M11212%N/AN/A
#9
$334.6M134911%£994.6MN/A
#10
$830.2M53568%N/AN/A
Add Company

What Is Gyroscope Therapeutics?

Gyroscope Therapeutics is developing gene therapy beyond rare disease and using it to treat a leading cause of blindness, dry age-related macular degeneration (dry-AMD). Dry-AMD is the leading cause of permanent vision impairment for people aged 65 and over and there are no approved treatments. Research suggests that when a part of the immune system, the complement system, is overactive it leads to inflammation that damages healthy eye tissues. Our lead investigational therapy, GT005, is designed to restore balance to the complement system. The goal is to slow, or possibly stop the progression of dry-AMD. Patients in our ongoing Phase I/II clinical trial, known as the FOCUS study, receive a single dose of the therapy through an injection below their retina. We are also developing surgical devices and procedures designed to safely, precisely and consistently deliver one-time therapies into the eye. The Orbit Subretinal Delivery System (Orbit SDS) is designed to allow surgeons to access an area of the eye called the ?subretinal space? without needing to remove the vitreous (the gel-like substance that fills the eye) or make a hole in the retina. This is important as it may increase the likelihood of treatment success by delivering therapies to critical target tissues while keeping the vitreous and retina intact. In addition to developing the Orbit SDS for delivery of our own therapies, Gyroscope will partner and license the technology to other gene and cell therapy companies. Syncona and Cambridge Innovation Capital helped us create the only retinal gene therapy company to combine discovery research, drug development, a manufacturing platform and surgical delivery capabilities. Headquartered in London, UK, with a U.S. headquarters near Philadelphia, PA, we are building a pipeline of medicines, surgical procedures and delivery devices to preserve sight and fight the devastating impact of blindness. For more information go to: www.gyroscopetx.com

keywords:N/A

$269.5M

Total Funding

61

Number of Employees

$4.7M

Revenue (est)

-69%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Gyroscope Therapeutics News

2021-11-09 - Gyroscope Therapeutics Receives Up To $60M Equity Investment From Sanofi

Gyroscope Therapeutics Holdings plc, a London, UK-based clinical-stage gene therapy company focused on diseases of the eye, received an up to $60m equity investment from global biopharmaceutical company Sanofi. Sanofi will invest $40.0m in Gyroscope initially, at a premium to Gyroscope’s prior ...

2021-11-08 - Gyroscope Therapeutics Announces Sanofi Investment of up to $60 Million

LONDON – 8 November 2021 – Gyroscope Therapeutics Holdings plc (Gyroscope), a clinical-stage gene therapy company focused on diseases of the eye, today announced that Sanofi, a global biopharmaceutical company, has committed to invest up to USD $60.0 million (GBP £44.5 million) in equity in Gyro ...

2021-11-08 - Gyroscope Therapeutics Announces Sanofi Investment of Up to $60 Million

Gyroscope Therapeutics Holdings plc (Gyroscope), a clinical-stage gene therapy company focused on diseases of the eye, today announced that Sanofi, a global biopharmaceutical company, has committed to invest up to USD $60.0 million (GBP £44.5 million) in equity in Gyroscope. Sanofi will invest $ ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$11.3M61-2%N/A
#2
N/A61-10%N/A
#3
$13.7M615%N/A
#4
$8M615%N/A
#5
$8.2M617%N/A